We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
68.00 | 0.56% | 12,118.00 | 12,120.00 | 12,124.00 | 12,162.00 | 11,966.00 | 11,966.00 | 2,561,221 | 16:35:21 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.56 | 187.91B |
By Adam Clark
AstraZeneca PLC (AZN.LN) said Friday that the U.S. Food & Drug Administration agency has approved its Lynparza drug for treatment of patients with metastatic breast cancer.
The biopharmaceutical company said Lynparza reduced the risk of disease progression or death by 42% compared with standard chemotherapy in clinical trials. The authorization is the third indication approved for Lynparza in the U.S., where it is already used to treat ovarian cancer.
AstraZeneca said that as part of its oncology collaboration with Merck & Co. Inc. (MRK) it will receive $70 million in externalization revenue following the new approval. The agreement sees AstraZeneca potentially eligible for over $6 billion in externalization revenue in the form of sales and approval-related payments, said the company.
AstraZeneca shares at 1619 GMT were up 13 pence, or 0.3%, at 5,145 pence.
Write to Adam Clark at adam.clark@dowjones.com
(END) Dow Jones Newswires
January 12, 2018 11:46 ET (16:46 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions